Background: Cytotherapy products can be described as “living drugs”.
Cytotherapy is the swiftest growing fields in the treatment of cancer, heart diseases, aging
population and neuromuscular ailments. Biomimetic approaches are processes developed
by humans such as devices, substances, or systems that mimic nature or natural processes.
Objective and Method: It aims at developing a base for personalized medicine with
allogeneic, autologous and xenogenic therapies where cells are modified for target
selection. Such drug delivery methods appear to be complex and challenging. Literature
for approximately past two decades was collected and reviewed for the present article.
Results and Conclusion: The opportunities and challenges in cytotherapy have been classified,
discussed and demystified. Various process inputs, materials and process conditions
required in bioprocessing and preservation have been discussed at length. The review
also focuses on the regulatory requirements in India, Europe and U.S.